BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 20595005)

  • 21. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
    Zhang X; Li W; Olumi AF
    Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells.
    Palacios C; Yerbes R; López-Rivas A
    Cancer Res; 2006 Sep; 66(17):8858-69. PubMed ID: 16951203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins.
    Lee SJ; Noh HJ; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
    Int J Oncol; 2011 Feb; 38(2):485-92. PubMed ID: 21170508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis.
    Jang JH; Park JS; Lee TJ; Kwon TK
    Cancer Lett; 2010 Jan; 287(2):224-30. PubMed ID: 19632032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
    Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
    Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin.
    Schultze K; Böck B; Eckert A; Oevermann L; Ramacher D; Wiestler O; Roth W
    Apoptosis; 2006 Sep; 11(9):1503-12. PubMed ID: 16820965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation.
    Kim YH; Lee YJ
    J Cell Biochem; 2007 Mar; 100(4):998-1009. PubMed ID: 17031854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition.
    Morales JC; Ruiz-Magaña MJ; Ruiz-Ruiz C
    Mol Immunol; 2007 Apr; 44(10):2587-97. PubMed ID: 17257681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
    Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
    J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells.
    Lee TJ; Jang JH; Noh HJ; Park EJ; Choi KS; Kwon TK
    J Cell Biochem; 2010 Apr; 109(5):885-95. PubMed ID: 20127709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
    Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
    Su L; Liu G; Hao X; Zhong N; Zhong D; Liu X; Singhal S
    Eur J Cancer; 2011 Nov; 47(16):2471-8. PubMed ID: 21726997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
    Venza I; Visalli M; Oteri R; Teti D; Venza M
    Int Immunopharmacol; 2014 Aug; 21(2):439-46. PubMed ID: 24946096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway.
    Wang WQ; Zhang H; Wang HB; Sun YG; Peng ZH; Zhou G; Yang SM; Wang RQ; Fang DC
    Mol Diagn Ther; 2010 Jun; 14(3):155-61. PubMed ID: 20560677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.